ACR meeting to highlight digital mammography
With Food and Drug Administration approval for a full-field digital mammography system finally arriving this year, the new imaging technique will be a hot topic at the American College of Radiology’s 29th conference on breast cancer in San
With Food and Drug Administration approval for a full-field digital mammography system finally arriving this year, the new imaging technique will be a hot topic at the American College of Radiologys 29th conference on breast cancer in San Francisco.
The meeting will be held April 8 through 11 at the San Francisco Hilton.
In addition to digital mammography, panels at the convention will cover malpractice, breast cancer diagnosis, breast pathology, and management dilemmas.
The FDA gave premarket approval for GE Medical Systems full-field digital mammography unit, the Senographe 2000D, in February. GE will display the system at the conferences exhibit hall, said Amy Hobert, GEs mammography marketing manager.
We wont be doing a lecture (using the system) but we will have a hands-on demonstration, and well have written information about the machine, Hobert said.
GE has sold 15 Senographe 2000Ds in the U.S. and 25 in Europe, according to Hobert.
GE has FDA approval to market the $500,000 unit for hard-copy use only. This means system users will be limited initially to reading digitally processed hard copies. Marketing the unit as a hard-copy device will give clinicians time to become familiar with the new technology before its marketed in soft-copy, said Charlie Young, GE spokesperson (SCAN 2/16/00).
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Contrast-Enhanced Mammography Study Reveals 24 Percent Lower Sensitivity with Moderate/Marked BPE
April 30th 2025In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.
